Redeye: Moberg Pharma - No major drama in 3Q18
From our perspective, the outcome in 3Q18 was not that dramatic. The investment case is intact, with a growing profitable OTC business forming a base and a possible big up-side with MOB-015 (first top-line data 4Q19).
Read more and download the Research Update: https://www.redeye.se/company/moberg-pharma/581607/moberg-pharma-no-major-drama-3q18
Start following companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/